Already priced domestically at a deep discount to counterpart PD-1s in the US, Beigene's tislelizumab could potentially get the first global approval for a China-originated drug in this class, as the immuno-oncology sector as a whole continues to come under pressure in China.

The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker

A number of new medicines are moving closer to the EU market after the European Medicines Agency recommended in favor of their approval. 

Any delays caused by unpredictable regulatory reviews related to the export of genetic materials threaten to derail the inclusion of China in international clinical trials, caution two trade groups representing the pharma industry in the country.